Conference Highlights ASH

Conference Highlights ASH

Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia

Conference Highlights ASH

Safety and Efficacy of Obinutuzumab (GA101) with Fludarabine Cyclophosphamide or Bendamustine in the Initial Therapy of Patients with Chronic Lymphocytic Leukemia: Results from the Phase 1b GALTON Trial

Conference Highlights ASH

Chronic Lymphocytic Leukemia: A New Treatment Era is Born

Conference Highlights ASH

Head-To-Head Comparison of Obinutuzumab Plus Chlorambucil versus Rituximab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia and Coexisting Medical Conditions: Final Stage 2 Results of the CLL11 Trial

Conference Highlights ASH

Siltuximab: Monoclonal Antibody Relieves Symptoms of Castleman’s Disease

Conference Highlights ASH

More Transplants Made Possible Through Haploidentical Donors

Caroline Helwick

Conference Highlights ASH

Hospital Readmission After Stem-Cell Transplant Decreases Survival

Conference Highlights ASH

JAK1/2 Inhibitor Ruxolitinib Improves Survival in High-Risk Myelofibrosis

Conference Highlights ASH

Ready-Made Platelets? A Boon for Patients If It Works

Neil Canavan, Neil Canavan

Conference Highlights ASH

High Morbidity Burden Borne Years Later by Survivors of Transplant

Caroline Helwick, Caroline Helwick

1
2
3
4

Page 3 of 4
Results 21 - 30 of 35

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.